Received 7 April 2006/Accepted 14 August 2006
|
|
- Megan Butler
- 5 years ago
- Views:
Transcription
1 JOURNAL OF VIROLOGY, Nov. 2006, p Vol. 80, No X/06/$ doi: /jvi Copyright 2006, American Society for Microbiology. All Rights Reserved. Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir John D. Baxter, 1 * Jonathan M. Schapiro, 2 Charles A. B. Boucher, 3 Veronika M. Kohlbrenner, 4 David B. Hall, 4 Joseph R. Scherer, 4 and Douglas L. Mayers 4 Cooper University Hospital/UMDNJ-Robert Wood Johnson Medical School, Camden, New Jersey 1 ; Stanford University, Stanford, California 2 ; Eijkman-Winkler Center, University Medical Center Utrecht, Utrecht, The Netherlands 3 ; and Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 4 Received 7 April 2006/Accepted 14 August 2006 Tipranavir is a novel, nonpeptidic protease inhibitor of human immunodeficiency virus type 1 (HIV-1) with activity against clinical HIV-1 isolates from treatment-experienced patients. HIV-1 genotypic and phenotypic data from phase II and III clinical trials of tipranavir with protease inhibitor-experienced patients were analyzed to determine the association of protease mutations with reduced susceptibility and virologic response to tipranavir. Specific protease mutations were identified based on stepwise multiple-regression analyses of phase II study data sets. Validation included analyses of phase III study data sets to determine if the same mutations would be and to assess how these mutations contribute to multiple-regression models of tipranavir-related phenotype and of virologic response. A tipranavir mutation score was developed from these analyses, which consisted of a unique string of 16 protease positions and 21 mutations (10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D, and 84V). HIV-1 isolates displaying an increasing number of these tipranavir resistance-associated mutations had a reduced phenotypic susceptibility and virologic response to tipranavir. Regression models for predicting virologic response in phase III trials revealed that each point in the tipranavir score was associated with a 0.16-log 10 copies/ml-lower virologic response to tipranavir at week 24 of treatment. A lower number of points in the tipranavir score and a greater number of active drugs in the background regimen were predictive of virologic success. These analyses demonstrate that the tipranavir mutation score is a potentially valuable tool for predicting the virologic response to tipranavir in protease inhibitor-experienced patients. * Corresponding author. Mailing address: Division of Infectious Diseases, Suite 513, Cooper Plaza, Camden, NJ Phone: (856) Fax: (856) baxter@umdnj.edu. Published ahead of print on 23 August Current treatment of human immunodeficiency virus (HIV) infection involves the concomitant administration of at least three antiretroviral medications among the classes of nonnucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and to a lesser extent entry inhibitors (1a). Antiretroviral drugs have limited efficacy when used as monotherapy, in part due to the rapid emergence of drug resistance mutations that often have a significant impact on the efficacy of other members of that same class of inhibitors (13). This effect is most apparent within the class of NNRTIs, for which a single mutation in viral reverse transcriptase can confer cross-resistance to all other members of the current NNRTI class. Various degrees of cross-resistance among the PIs have been observed. This has resulted in limited or no options for the use of another PI following multiple PI failure. There is clearly a need for novel PIs with activity against PI-resistant HIV type 1 (HIV-1) and distinct patterns of PI cross-resistance. Tipranavir demonstrates unique characteristics that offer potential therapeutic advantages to PI-experienced patients. Tipranavir is a novel, nonpeptidic inhibitor of the HIV-1 protease manufactured by Boehringer-Ingelheim Pharmaceuticals, Inc. Tipranavir s antiviral activity was evaluated with several cell culture systems and against clinical HIV-1 strains, and it was found to be a potent inhibitor of wild-type HIV-1 replication, with 50% inhibitory concentrations (IC 50 s) ranging from 0.03 to 0.07 M and 90% inhibitory concentrations ranging from 0.07 to 0.18 M (1, 12, 17, 19). In vitro passage studies showed that the development of resistance to tipranavir is slow, requiring up to 9 months in culture (5). The presence of six mutations, I13V, V32I, L33F, K45I, V82L, and I84V, was required to confer a 10-fold decrease in tipranavir susceptibility. The long duration of time combined with the high number of genotypic mutations required to evolve resistance to tipranavir in vitro suggest a high genetic barrier for tipranavir. An in vitro study using 105 clinical HIV-1 isolates from patients with prior exposure to other PIs demonstrated that tipranavir retains activity against more than 90% of isolates resistant to other PIs (11). A phase II clinical trial of ritonavirboosted tipranavir in highly treatment-experienced patients with documented PI resistance demonstrated the potent antiviral activity of ritonavir-boosted tipranavir (10). Subsequently, phase III clinical trials demonstrated significantly greater rates of virologic and immunologic responses for ritonavir-boosted tipranavir compared to other ritonavir-boosted PIs (2, 7). These data indicate that the resistance profile of tipranavir is distinct from that of other PIs in that mutations that lead to resistance to other PIs do not have the same impact on tipranavir susceptibility
2 VOL. 80, 2006 GENOTYPIC CHANGES IN HIV-1 ASSOCIATED WITH TIPRANAVIR In this analysis, we describe the relationship between genotypic changes in HIV-1 protease and tipranavir phenotypic susceptibility in HIV-1 isolates from highly treatment-experienced patients. We also examine the relationship between specific protease mutations and the virologic response to tipranavir in phase II and III clinical trials. The objective of this analysis is to identify a set of HIV-1 protease mutations that can be used to predict either susceptibility or response to ritonavir-boosted tipranavir treatment. MATERIALS AND METHODS Viral isolates. HIV-1 resistance data were analyzed from six clinical trials conducted in North America, Latin America, and Europe with HIV-positive adult patients to evaluate the efficacy and safety of tipranavir boosted with ritonavir. Three phase II dose-ranging trials (1182.2, , and ), two phase III controlled trials ( and ), and a phase IIb/III pharmacokinetic and safety trial of dually boosted PI use ( ) were included. Genotyping and phenotypic resistance testing was conducted with stored baseline plasma samples of patients entered in trials and In all other trials, baseline genotyping was conducted during the screening phase. All baseline samples from these trials were obtained from patients while on a failing drug regimen. Resistance testing of on-treatment samples was conducted with stored samples on the basis of treatment failure. Trials and differed from the other trials in that only clinical virologic failure entry criteria were required, while subsequent trials required genotypic resistance to be documented prior to entry. All patients were antiretroviral treatment experienced. However, by design, patients in trial were NNRTI naive; patients in trial had exposure to only a single PI; and patients in all other trials were triple-class experienced, including at least two PI-based regimens. The nucleotide sequence data for isolates in these analyses has been deposited in GenBank (accession numbers DQ to DQ880940). Laboratory assays. Plasma HIV-1 RNA genotyping was conducted using either the TruGene 6.0 and 7.0 [Bayer] or Virtual Phenotype assays (version 3.6; [VIRCO]). The TruGene assay produced a 1.3-kb sequence that included the entire protease gene and the first 250 amino acids of the reverse transcriptase gene, whereas the Virtual Phenotype assay sequenced the entire protease gene and the first 400 amino acids of the reverse transcriptase gene. Codons with mixtures of mutant and wild-type (WT) amino acids were considered mutant for these analyses. VIRCO Laboratories (Mechelen, Belgium) was the designated reference laboratory for the HIV-1 phenotypic analyses using the Antivirogram recombinant virus assay. Results are reported as n-fold WT values, comparing the IC 50 for the clinical sample to that for the concurrently run WT viral control. Plasma HIV-1 RNA levels were measured using the Roche Amplicor HIV-1 Monitor assay, version 1.5 (Roche Diagnostic Systems, Inc., Ontario, Canada) or the Roche UltraSensitive method, version 1.5. Statistical methods. (i) Introduction. The analysis plans consider the tipranavir phenotype (IC 50 n-fold change (FC) from WT value) and the change from the baseline in log 10 plasma HIV RNA levels to be dependent variables. A screening regression analysis of every deviation at each protease codon from subtype B (the assay reference), as a single independent variable, was the basis for selecting the mutations considered for the stepwise linear regression. Phase II study data sets were used to create a tipranavir mutation score. Validation included evaluating phase III study data sets to see whether the same mutations would be when repeating these analyses and checking to see how the tipranavir score contributes to multiple-regression models of phenotype and virologic response. (ii) Data sets used for tipranavir score derivation. The five data sets used to derive the tipranavir mutation score were labeled and identified as models A through E. The relationship between protease genotype and phenotypic susceptibility to tipranavir was investigated with the first three data sets. The first data set, model A, addresses resistance by other protease inhibitors prior to treatment with tipranavir. It includes patients with both a drug resistance genotype and phenotype (n 287). The second data set, model B, addresses resistance by exposure to tipranavir on a background of mutations by other protease inhibitors. This model includes all patients with at least one available on-treatment specimen that yielded both a drug resistance genotype and phenotype (n 72), with the last available assay results used for analysis. The third data set, model C, addresses extensive protease exposure, including exposure to tipranavir. Therefore, it includes the last available specimen with both assay results for all patients in either model A or B or both (n 293.) The relationship between protease genotype and virologic response to tipranavir was investigated with two data sets. To examine the association between baseline genotype and the 2-week change from baseline in plasma HIV-1 RNA levels, the data set model D included all patients enrolled in the phase II dose selection trial (trial ) with a 2-week virologic assessment of tipranavir functional monotherapy (n 204). The data set model E was designed to examine the association between the baseline genotype and the 24-week change from baseline in plasma HIV-1 RNA levels and thus included all tipranavir patients enrolled in phase II trials for whom both results were available (n 298). Furthermore, the relationship between protease genotype and virologic rebound was investigated with a data set that included all tipranavir patients enrolled in phase II trials who had both a baseline and at least one on-treatment protease genotype determination. The existence of an on-treatment genotype, requiring a specimen with 1,000 copies/ml HIV-1 RNA, was considered evidence of virologic rebound. Baseline and on-treatment genotype sequences were compared to identify emergent mutations. (iii) Regression methods for tipranavir mutation score derivation. Initial screening of observed mutations was conducted using linear regression models, with the independent variable being an indicator for each mutation and the dependent variable being the log 10 tipranavir IC 50 degree of change from the WT or change from baseline in log 10 plasma HIV-1 RNA levels. The estimated regression coefficient, median IC 50 n-fold change (or change in HIV-1 RNA level) for those isolates with the mutation and those without it, and the nominal statistical significance of the difference between the slope coefficient and zero were calculated for all identified amino acid mutations. The resulting list of mutations considered for forward stepwise multiple regression was then on the basis of at least five observations, a P value of 0.05 for the regression slope, and a positive difference between the median log 10 tipranavir IC 50 n-fold change from the WT value or change from baseline in log 10 plasma HIV-1 RNA level for those isolates with the mutation compared to those without the mutation. These criteria eliminate any rare mutations and mutations associated with increased susceptibility. Selection for or against a mutation by exposure to tipranavir was considered in refining the list. Although the L90M and 82A mutations did not meet our analysis criteria, these mutations were also considered due to their previously reported association with resistance to tipranavir and other PIs as well (4, 8, 11). When multiple substitutions occurred at a given codon, whether to consider each separately or several as a group in the stepwise multiple-regression analysis was based on (i) whether there were differences in the simple linear regression models for the different amino acids and (ii) whether the P value for the combined amino acids was smaller than those for the individual amino acids (which would indicate that all were having consistent effects). When there were differences or the P value was larger, the mutations were considered separately. The mutations were then included in each of the five forward stepwise regression analyses of the data sets described above (models A to E). At each step, the mutation with the strongest relationship to the dependent variable after adjustment for previously mutations was identified on the basis of the P value for its regression coefficient. Selection continued until no remaining mutations reached a P value of 0.05 as the last term added to the model. The set of mutations contributing to the tipranavir mutation score was then derived by aligning the results of the five analyses and choosing those that were by at least two analyses or by one analysis and also in vivo by exposure to tipranavir. (iv) Regression methods for tipranavir mutation score validation. Matched genotypic and phenotypic results (n 523) as well as treatment response data (n 569) were analyzed from three phase III trials of tipranavir boosted with ritonavir. Screening criteria included genotypic evidence of resistance to protease inhibitors. An independent analysis of these data repeated the steps in the analysis of the phase II data. Univariable analyses of genotype versus phenotype and genotype versus response were the basis for selection of mutations included in stepwise multiple-regression analyses. These stepwise analyses identified mutations that made significant contributions to the prediction of the dependent variable, i.e., phenotype or viral response. Differences from the phase II analyses were identified and evaluated to determine whether to adjust the score. The mutations from the phase II analyses were then used in multiple logistic regression analyses to evaluate how well the models predict the phase III data. The baseline tipranavir score, derived by counting the number of tipranavir-associated mutations observed (each considered as one point in the tipranavir mutation score), was included in regression models including enfuvirtide use and the number of active antiretrovirals in the optimized background regimen, which
3 10796 BAXTER ET AL. J. VIROL. was based on the genotypic interpretation of susceptibility. This approach yielded evidence of the predictive value of the tipranavir mutation score. RESULTS Screening analyses: phase II trials. Of 99 protease codons, the 5 sets of one-way regression analyses identified 45 amino acids at 29 codons that were statistically significantly associated with phenotypic resistance or reduced virologic response to tipranavir in at least one analysis. The data sets for association of genotype and phenotype (models A, B, and C) identified 43 amino acids at 28 codons, of which 1, 10I, was not taken into the multiple-regression analyses because it was against by tipranavir exposure and was not identified by any genotype to response analysis. s 20M, 20V, 35N, 37E, 39Q, 66F, 82A, 91S, 92K, and 92R were significant only when analyzing the genotype associated with exposure to other protease inhibitors (model A). s 10V, 16A, 24M, 33I, 33V, 34D, 36L, 69K, 82L, 82T, 89M, and 89V were significant only when mutations associated with tipranavir exposure were included in the analysis (models B and C). s 13V, 33F, 35D, 36I, 43T, 46L, 47V, 54V, 58E, 62V, 71V, and 84V were significant in all three analyses of phenotype. The data sets for association of genotype and virologic response identified 17 amino acids at 16 codons, of which one, 13L, was not taken into the multiple-regression analyses because it was against by tipranavir exposure and was not identified by any of the genotype-to-phenotype analysis. s 55Q, 71V, 84V, and 91S were significant for the 2-week response (model D); 13L, 16A, 36I, 46L, 69K, and 89V were significant for the 24-week response (model E); and 13V, 20M, 32I, 33F, 35G, 47V, and 54M were significant for both. Three mutations were added to the list taken into multipleregression analysis because they appeared to be for by tipranavir exposure: 66V, 74A, and 83D. The 90M mutation was taken into the multiple-regression analysis because of its prior association with phenotypic resistance to tipranavir (4, 11). The 82A mutation was also taken into the multiple regression because like 90M it is considered a major protease mutation for other PIs; however, it appeared that the 82A mutation was against with exposure to tipranavir. The list of mutations assessed in stepwise multiple regression was as follows: 10V, 13V, 16A, 20 M/R/V, 24M, 32I, 33F/I/V, 34D, 35D/N/G, 36I/L, 37E, 39Q, 43T, 46L, 47V, 54M/V, 55R/Q, 58E, 62V, 66F/V, 69K, 71V, 72E, 74A/P, 82A/F/L/T, 83D, 84V, 89M/V, 90M, 91S, 92K/R (47 mutations). The majority of these mutations identified by the screening analyses have not been reported as being natural polymorphisms in untreated patients (20). s at six positions were associated with significantly increased susceptibility to tipranavir compared with that of isolates that did not have the mutation (model C): 18L (median FC 0.5; P 0.035), 30N (median FC 0.5; P 0.001), 50V (median FC 0.7; P 0.021), 54L (median FC 0.7; P 0.018), 77I (median FC 1.0; P 0.011), and 88D (median FC 0.6; P 0.001). The most common, 77I, was observed in 102 (35%) isolates. The D30N mutation in 26 isolates (9%) and N88D in 26 isolates (9%) have been associated with nelfinavir resistance, and the I50V mutation in 19 isolates (6%) has been associated with amprenavir resistance (8). With the goal of developing a score based on mutations associated with tipranavir resistance, these six mutations were not considered further. Multiple stepwise regression analyses: phase II trials. Fortyseven mutations, by screening analyses as described above, were taken into the multiple stepwise regression analysis models and reduced to 28 mutations identified in at least one of the five stepwise models (Table 1). s identified in only one of the stepwise regression models or mutations which were not identified in emergence analyses were excluded. These were mutations 35N, 37E, 39Q, 55Q, 72E, 82F, and 91S, which are not included in determining the tipranavir mutation score. Thus, the 21 tipranavir-associated mutations (16 codons) identified from phase II trials consisted of the following: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D, and 84V. Table 1 demonstrates the mutations by each of the stepwise multiple-regression methods for the five analysis sets. With phenotype as the dependent variable, r 2 values achieved were from 0.49 to 0.82 (models A, B, and C). Effect estimates of the contribution of each mutation to reduced susceptibility ranged from a 0.10 to 1.28 log 10 IC 50 n-fold change in models that included baseline isolates (models A and C), while the range was from 0.37 to 1.73 in the model that included only on-treatment observations (model B). The mutations include 17 amino acids at 14 codons that were significant in the most extensive univariable analysis of phenotypic resistance (model C). At all codons, 10V, 13V, 20R, 33F, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, and 84V had P values of 0.01 in the univariable analysis. The mutation 83D was one of three included in the analysis because of evidence that it was for by exposure to tipranavir. The mutation 35G was identified in univariable analysis models of virologic response. Screening analyses: phase III trials. As with the phase II trials, each mutation observed at baseline was evaluated by comparing those viruses with the mutation present to those that were without the mutation. The baseline phenotype available for patients in trials , , and was examined to see which mutations were associated with reduced susceptibility to tipranavir. The baseline genotype for patients in phase III trials ( and ) was examined to see which mutations were associated with reduced 24-week HIV RNA response to tipranavir. The baseline genotype and baseline phenotype analysis of phase III data identified 10 mutations that had not been identified as significant in the univariable phase II analyses: 11I, 19P, 22V, 60E, 70E, 72L, 82C, 83D, 85V, and 90M. The 83D mutation had been included in the phase II multivariable analysis on the basis of selection with exposure to tipranavir and was previously for inclusion in the tipranavir mutation score. The 90M mutation was included in the phase II multivariable analysis because of early observations that it was associated with tipranavir resistance but was not for inclusion in the tipranavir mutation score. Thus, the string of mutations evaluated in multiple stepwise regression analyses of phase III included the following (the asterisk indicates added new mutations based on phase III univariable analyses): 10V, 11I*, 13V, 16A, 19P*, 20M, 20R,
4 VOL. 80, 2006 GENOTYPIC CHANGES IN HIV-1 ASSOCIATED WITH TIPRANAVIR TABLE 1. Summary of stepwise multivariable regression analyses and mutations comprising the tipranavir mutation score: phase II trials Multiple-regression analysis result b Genotype-to-phenotype relationship Genotype-to-response relationship analyzed a Model A (baseline) c Model B (on-treatment) d Model C (on-treatment or baseline) e Model D (2-wk functional monotherapy) f Model E (24-wk, LOCF) g Tipranavir score mutation h 20V, 22V*, 24M, 32I, 33I, 33F, 33V, 34D, 35D, 35N, 35G, 36I, 36L, 37E, 39Q, 43T, 46L, 47V, 54A, 54 M, 54V, 55R, 55Q, 58E, 60E*, 62V, 66F, 66V, 69K, 70E*, 71V, 72E, 72L*, 74A, 74P, 82A, 82C*, 82L, 82F, 82T, 83D, 84V, 85V*, 89M, 89V, 90M, 91S, 92K, and 92R. This new string is called the modified string in analyses described below. Multiple stepwise regression analyses: phase III trials. The multivariable stepwise regression was performed once with the string of mutations identified by the phase II analyses. It was then repeated using the modified string as described above: the same string of mutations plus the mutations that were significant for the first time in the phase III univariable analyses. The purpose was to determine how much the resultant mutation set was dependent on the initial selection step. The result for the genotype-to-phenotype multiple stepwise regression was a set of 16 mutations at 13 codons (10V, 35D/G, 43T, 46L, 47V, 54M/V, 58E, 60E, 74P, 82F/T, 83D, 84V, and 90M). Of these, 60E was the only mutation to be from among the eight that were added in the modified string. Only 10V 10V V V 13V 13V V 20M 20M M M 20R 20R R R 20V 20V V V V 33F 33F F 35G 35G G 35N 35N I 36I I I 37E 37E Q 39Q T 43T T T T 46L 46L L L L L 47V 47V V V V V V 54A 54A A A 54M 54M M 54V 54V V 55Q 55Q E 58E E E E 69K 69K K K K K 72E 72E E P 74P P P 82F 82F F T 82T T T 82L 82L L L 83D 83D D D 84V 84V V V V V 91S 91S 0.36 a identified in at least one multiple stepwise regression analysis model. b, estimated effect, the contribution of the mutation to the multiple-regression model expressed in log 10 IC 50 FC of tipranavir for models A, B, and C and expressed in log 10 HIV RNA for models D and E. c Two hundred eighty-seven isolates were tested; r d Seventy-two isolates were tested; r e Two hundred ninety-three isolates were tested; r f Two hundred four isolates were tested; r g Two hundred ninety-eight isolates were tested; r h counted in determining tipranavir mutation score. two other mutations were not previously seen in multiple stepwise regression for tipranavir: 35D and 90M. The 82F mutation, which had been significant in phase II phenotypic analyses but had not been included in the tipranavir mutation score, was again significant and remained a relatively rare mutation. Thus, four mutations that had not been included in the tipranavir mutation score were in these phase III models (35D, 60E, 82F, and 90M). These mutations were unsupported by anything other than genotypic-to-phenotypic relationships; neither a genotype-to-response relationship nor emergence with tipranavir exposure was noted. They were therefore not promoted to inclusion in the tipranavir mutation score because of this lack of corroboration. The remaining 12 mutations had been in phase II analyses and included in the tipranavir mutation score. Applying both strings to the 24-week HIV RNA response (last observation carried forward [LOCF]) the same set of five mutations at four codons: 47V, 54M, 54V, 69K, and 82A. All except 82A are part of the tipranavir mutation score
5 10798 BAXTER ET AL. J. VIROL. FIG. 1. Backbone tracing of HIV-1 protease with tipranavir bound into the active site of the enzyme. The positions of the mutations that are part of the tipranavir score are highlighted in red or yellow on both monomers (although for clarity the labels appear only once per monomer). derived in the analyses of phase II trials. 82A was a significant predictor of good response, as evidenced by a negative parameter estimate, and therefore was not included in the tipranavir mutation score. Nothing emerging in the phase III analyses met the standards set for inclusion in the tipranavir-associated mutations. s found to be associated with the baseline phenotype were not associated with the response to tipranavir in any analyses and were not emergent in the phase II analyses of viral genotypes from patients exposed to tipranavir. Therefore, no modification of tipranavir mutation score determination was required on the basis of this analysis of the phase III baseline phenotype and 24-week response results. Thus, the validated tipranavir score mutations include 16 protease positions, 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D, and 84V (Fig. 1). These mutations are distributed throughout the entire protease as follows: L33F, V82L/T, N83D, and I84V in the active site, E35G and M36I in the ear flap, K43T, M46L, I47V, I54A/M/V, and Q58E in the flap, L10V, I13V, and K20M/R/V in the cheek turn, and H69K and T74P in the cheek sheet (16, 22). The accumulation of these mutations is required to predict decreased phenotypic susceptibility or diminished antiviral responses to tipranavir. Tipranavir mutation score versus phenotype: phase II and III trials. To further understand the relationship between the tipranavir mutation score and tipranavir phenotypic susceptibility, phenotypic data were combined for all phase II and III clinical trials. Table 2 shows the median IC 50 n-fold change from the WT value for baseline HIV-1 isolates according to the number of tipranavir score mutations. Tipranavir mutation scores of 0 or 1 were associated with a median n-fold change in tipranavir susceptibility of 1. Increasing tipranavir mutation score numbers were associated with a higher median degree of change from the WT value for tipranavir. A tipranavir mutation score of 4 was associated with a median n-fold change in tipranavir susceptibility of 2, while a score of 8 was associated with an n-fold change of Although the number of isolates with tipranavir mutation scores of greater than 7 was limited, there was clearly a marked reduction in tipranavir susceptibility. Overall these pooled data demonstrate that with an increasing tipranavir mutation score there is a reduction in tipranavir susceptibility. Comparison of phenotypic susceptibilities of baseline isolates to current protease inhibitors: phase II and III trials. Table 3 compares median HIV-1 phenotypic susceptibilities to tipranavir and the other currently available protease inhibitors from phase II and III clinical trials. Pooled baseline data from the phase II trials in which patients had exposure to one or more protease inhibitors show a median n-fold change of 1 TABLE 2. Median n-fold change from WT value for tipranavir IC 50 by tipranavir mutation score among baseline HIV-1 isolates from participants in phase II and III tipranavir trials No. of tipranavir score mutations a No. (%) of isolates with score Median fold change (IQR b )inic 50 of tipranavir 0 80 (9.9) 0.7 (0.4, 1.0) (13.0) 0.9 (0.6, 1.4) (14.6) 1.1 (0.6, 1.9) (19.6) 1.4 (0.7, 2.6) (18.9) 2.0 (1.0, 4.1) (14.1) 3.1 (1.7, 7.0) 6 49 (6.0) 3.3 (1.6, 8.7) 7 25 (3.1) 3.9 (2.7, 12.5) 8 6 (0.7) 14.7 (4.9, 19.8) 9 1 (0.1) 52.5 (52.5, 52.5) a s used to determine tipranavir mutation score: L10V, I13V, K20M/ R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D, and I84V. b IQR, interquartile range.
6 VOL. 80, 2006 GENOTYPIC CHANGES IN HIV-1 ASSOCIATED WITH TIPRANAVIR TABLE 3. Baseline phenotypic susceptibilities of clinical HIV-1 isolates to tipranavir and existing protease inhibitors in phase II and III tipranavir trials Clinical trial(s) Median tipranavir mutation score (IQR a ) Median fold change from WT IC 50 (n b ) for antiretroviral drug Tipranavir Amprenavir Atazanavir Indinavir Lopinavir Nelfinavir Saquinavir Ritonavir Phase II trials 2 (1, 4) 1.0 (294) 2.8 (289) Not done 7.9 (289) 23.7 (255) 26.9 (294) 3.2 (294) 23.6 (291) Phase III and 3 (2, 4) 1.7 (454) 12.2 (445) 55.3 (456) 41.0 (423) 87.4 (452) 40.7 (452) 20.1 (450) (449) trials Phase IIb/III trial 5 (3.5, 6) 4.7 (70) 41.0 (71) 99.9 (71) 56.6 (69) (71) 41.7 (71) 46.2 (71) (71) a IQR, interquartile range. b n, no. of isolates tested. for tipranavir, compared to 2.8 for amprenavir and 23.7 for lopinavir. In the large phase III trials, the median IC 50 n-fold change for tipranavir and the other protease inhibitors was higher than in earlier phase II trials, since patients in these studies had greater protease inhibitor exposure and more primary protease mutations. This is seen to an even greater extent in median n-fold change values for trial , which included patients with the most highly protease inhibitor-resistant viruses. Tipranavir mutation score versus response: phase II and III trials. To examine the treatment response in relation to the tipranavir mutation score, HIV RNA reductions were examined for phase II and III trials. Table 4 shows the change in HIV RNA from the baseline through 2 and 24 weeks, combining data from the phase III and studies with data from patients receiving the same dose of boosted tipranavir in the and studies. Patients whose virus had 0 or 1 mutation achieved a median reduction in HIV RNA of 1.3 log 10 copies/ml at 2 weeks and 2.1 log 10 copies/ml at 24 weeks. Although 2-week responses were similar for those with two to seven tipranavir score-determining mutations, the virologic responses at 24 weeks were diminished. The dropoff in response at 24 weeks for these individuals has been attributed to the frequency of broad three-class drug-resistant viruses and a lack of active background therapy that could be administered with tipranavir (data not shown) (23). Although there were few patients whose viruses had baseline tipranavir mutation scores of 8, virologic responses were poor at 2 and 24 weeks for these patients. TABLE 4. Treatment responses at 2 and 24 weeks by tipranavir mutation score in phase II a and III trials No. of tipranavir score mutations Median change in HIV RNA b (n c ) (IQR d ) at: 2wk 24wk (39) ( 0.91, 1.92) 1.84 (30) ( 0.57, 2.85) (96) ( 0.90, 1.71) 2.12 (84) ( 1.06, 2.72) (112) ( 0.87, 1.83) 1.30 (91) ( 0.31, 2.54) (177) ( 0.72, 1.83) 0.64 (151) ( 0.16, 2.29) (191) ( 0.63, 1.87) 0.58 (157) ( 0.11, 2.36) (111) ( 0.43, 1.89) 0.30 (103) ( 0.13, 1.69) (56) ( 0.23, 1.81) 0.51 (50) ( 0.05, 1.44) (20) ( 0.18, 1.79) 0.49 (18) ( 0.00, 2.84) (4) ( 0.11, 0.83) 0.08 (4) ( 0.01, 0.18) a Including only patients treated with the phase III twice-daily dose of 500 mg tipranavir boosted with 200 mg ritonavir. b Change in HIV RNA from baseline through week 2 (on treatment) or week 24 (LOCF) in log 10 copies/ml. c n, no. of patients. d IQR, interquartile range. Regression models for predicting virologic response: phase III trials. The tipranavir mutation score at baseline was used along with variables for enfuvirtide use and genotypic susceptibility to optimized background drugs to predict a 1-log HIV RNA decline in patients receiving tipranavir in phase III studies. Logistic regression models considered the week 2 response and the week 24 response. These models showed that both enfuvirtide use and the tipranavir mutation score were consistently and independently associated with the likelihood of obtaining a 1-log 10 -copies/ml HIV RNA reduction at weeks 2 and 24. At 24 weeks, patients who used enfuvirtide had a 3.6-fold greater chance of achieving a 1-log 10 -copies/ml HIV RNA reduction than those who did not; in addition, for each drug used in the background that was active by genotype, patients had a 48% higher chance of achieving a virologic response. Finally, for each additional single mutation counted in the tipranavir mutation score, the chances of achieving a 1-log 10 -copies/ml HIV RNA reduction at week 24 decreased by 21%. When plasma HIV RNA reduction was analyzed as a continuous variable including the same explanatory variables as in the logistic regression models, again enfuvirtide use and the tipranavir mutation score were significantly and consistently associated with the magnitude of HIV RNA reduction (Table 5). The number of active drugs in the background regimen was also significant. Each point in the tipranavir mutation score was associated with 0.04-log 10 -copies/ml-lower viral response at week 2 and a 0.16-log 10 -copies/ml-lower viral response at week 24. In summary, evaluating the patients who participated in trials and , mutations counted in the tipranavir mutation score were predictive of viral load responses to tipranavir-containing regimens. DISCUSSION Tipranavir is a novel, nonpeptidic inhibitor of HIV-1 protease that offers potential therapeutic advantages for PI-experienced patients. Tipranavir has activity against HIV-1 isolates broadly resistant to other protease inhibitors. Phase III clinical trials have demonstrated that patients treated with tipranavirritonavir achieve a superior virologic and immunologic response compared to those patients treated with other ritonavirboosted protease inhibitors (3). The results of these analyses suggest that the resistance profile of tipranavir is distinct from that of other protease inhibitors. In this analysis of predominantly subtype B HIV-1 isolates, a unique string of 16 protease positions with 21 mutations
7 10800 BAXTER ET AL. J. VIROL. Parameter TABLE 5. Multiple-regression models for virologic response in phase III tipranavir trials a Estimate (log 10 copies/ml) 2wk P value Virologic response at: Estimate (log 10 copies/ml) Tipranavir-associated reduction b Enfuvirtide use Active drugs in background regimen Tipranavir score a Change from baseline in log 10 HIV-1 RNA as a function of enfuvirtide use, number of active drugs in background regimen, and tipranavir score at baseline. b The tipranavir-associated reduction, or intercept, is the estimated HIV RNA reduction from baseline when enfuvirtide is not used, there are no active drugs in the background regimen, and the tipranavir score is zero. This is the effect of tipranavir extrapolated beyond the range of tipranavir scores for participants in phase III trials. 24wk P value (10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D, and 84V) was identified as being associated with a reduced susceptibility and diminished virologic response to tipranavir. These tipranavir score mutations were identified based on univariable and multivariable analyses of phase II clinical trial data and were subsequently validated using phase III clinical trial data. Analyses included genotype-to-phenotype comparisons, virologic response to treatment with tipranavir, and the emergence of new mutations upon treatment with tipranavir. The viral isolates in these studies were obtained from patients with exposure to multiple other protease inhibitors, and most displayed markedly reduced susceptibilities to other commercially available PIs. s counted in the tipranavir mutation score are not necessarily reflective of the de novo development of resistance for treatment-naive patients who receive tipranavir-ritonavir. An ongoing trial with this patient population will help define the protease resistance mutations that may emerge when tipranavir-ritonavir is used for initial therapy. A number of the tipranavir score mutations correlated with positions identified in vitro to be associated with reduced susceptibility to tipranavir, namely positions 10, 13, 33, 36, 54, 82, and 84 (4). However, several positions were identified in these analyses (codons 13, 35, 43, 58, 69, 74, and 83) that have not been associated with resistance to other protease inhibitors (9, 18, 21) ( demonstrating a novel resistance profile for tipranavir. Of particular clinical relevance is the fact that major protease mutations (30N, 48V, 50V/L, 82A/F, and 90M) associated with resistance to other protease inhibitors were not found to contribute to the tipranavir mutation score (9), and several (30N and 50V) were associated with increased susceptibility to tipranavir. Although associated with reduced susceptibility to tipranavir in testing of earlier clinical isolates (11), the 90M mutation was not included in the tipranavir mutation score due to the negative results of multiple multivariable analyses. The 90M mutation may serve as a marker for highly mutated viruses which are likely to contain other protease mutations associated with decreased tipranavir susceptibility. As shown in Fig. 1, the residues that are part of the tipranavir mutation score are not concentrated solely around the active site but rather are distributed throughout most of the protease structure (encompassing the active site, the extended flap, and the cheek area) (16). Preliminary comparative analysis of the X-ray structure of tipranavir complexed with the wild type or the Q7K I13V V32I L33F K45I V82L I84V mutant (mutations counted in the tipranavir mutation score are underlined) suggests that the hydrogen bond network between tipranavir and the active site residues remains largely unaltered (data not shown). However, detailed thermodynamic measurements indicate that tipranavir behaves in a unique manner compared to other available protease inhibitors by gaining or sustaining only minimal loss in binding enthalpy when bound to mutant proteases (14, 15). Increasing numbers of the tipranavir score mutations were associated with a reduced phenotypic susceptibility and a diminished virologic response to tipranavir. Although there were a limited number of isolates with a tipranavir mutation score of 8, clearly these viruses were associated with the highest n- fold change values, and a minimal response was seen in phase II and III trials. Therefore, these analyses would support a cutoff of 8 mutations of the tipranavir score group being predictive of full resistance and lack of efficacy with tipranavir. With 5 tipranavir score mutations, the overall median phenotypic FC was 3 and a diminished 24-week virologic responses were observed. Of note, as demonstrated with the multiple-regression models for virologic response in phase III trials, enfuvirtide use and the number of active background drugs also contributed to the virologic outcome. The tipranavir mutation score is a potentially valuable tool for predicting phenotypic susceptibility and virologic response to tipranavir. However, for an individual patient the utility of the tipranavir score for correctly predicting the response may be somewhat limited given the range of phenotypic values possible with each score and the number of other active drugs available to administer with tipranavir. Furthermore, certain limitations should be acknowledged, such as confounding factors (e.g., use of efavirenz in NNRTI-naive patients in trial , different doses of tipranavir and ritonavir in the three phase II trials, and possible undocumented nonadherence), which may have affected the predictive ability of the score. Thus, the potential for both false-positive and false-negative associations cannot be excluded. Validation of the tipranavir mutation score with the phase III clinical trial data supports the importance of this set of protease mutations; however, as more data become available in the future, further refinement of the score may be necessary, especially for patients infected with non-subtype-b HIV-1. The tipranavir mutation score was also highly predictive of virologic response with the multipleregression model using phase III data. Of note, use of active
8 VOL. 80, 2006 GENOTYPIC CHANGES IN HIV-1 ASSOCIATED WITH TIPRANAVIR drugs, such as enfuvirtide, along with tipranavir was associated with an improved virologic response. This emphasizes the importance of using tipranavir with other active agents with treatment-experienced patients to preserve drug activity and prevent the emergence of new resistance mutations. In summary, the requirement that multiple specific protease mutations are needed to confer a reduced phenotypic susceptibility and a decreased virologic response to tipranavir suggests that there is a high genetic barrier to the development of resistance to tipranavir. The majority of HIV-1 isolates obtained from protease inhibitor-experienced patients in phase II and III clinical trials retained susceptibility to tipranavir, exhibiting an IC 50 n-fold change, relative to the WT value, of 3. Most patients failing therapy with other currently available protease inhibitors are likely to benefit from a treatment regimen containing tipranavir-ritonavir, particularly if used in combination with other active agents, as seen in the phase III trials. These trials also demonstrated that despite extensive prior protease inhibitor exposure, patients had favorable virologic responses to tipranavir-ritonavir, with attenuation of the response as the number of baseline tipranavir score mutations increased. The tipranavir mutation score derived from these analyses represents a unique set of mutations which are capable of predicting the virologic response to tipranavir-ritonavir in protease inhibitor treatment-experienced patients. ACKNOWLEDGMENTS We thank Pierre Bonneau for helpful discussions and for providing the protease structure model and Peter Piliero for critically reviewing the manuscript. We are grateful to Paula McKenna (Virco, Ltd.) for providing phenotypes of the HIV-1 isolates. REFERENCES 1. Back, N. K. T., A. van Wijk, D. Remmerswaal, M. van Monfort, M. Nijhuis, R. Schuurman, and C. A. Boucher In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 14: a.Bartlett, J. G., H. C. Lane, and the Panel on Antiretroviral Guidelines for Adults and Adolescents, Office of AIDS Research Advisory Council. 4 May Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, p National Institutes of Health, Bethesda, Md. [Online.] 2. Cahn, P., and the RESIST-2 study team week data from RESIST-2: phase 3 study of the efficacy and safety of background therapy plus tipranavir/ ritonavir (TPV/r) or optimized ritonavir-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicenter trial in treatment-experienced HIV patients. Presented at the 7th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 14 to 18 November. 3. Cahn, P.I., and C. Hicks for the RESIST-2 and RESIST-1 study teams RESIST-1 (R-1) and RESIST-2 (R-2) 48 week meta-analyses demonstrate superiority of protease inhibitor (PI) tipranavir ritonavir (TPV/r) over an optimized comparator PI (CPI/r) regimen in antiretroviral (ARV) experienced patients. Presented at the 10th European AIDS Conference, Dublin, Ireland, 17 to 20 November. 4. Doyon, L., S. Tremblay, M. Cartier, and M. G. Cordingley In vitro susceptibility of HIV-1 to tipranavir. Antivir. Ther. 7:S Doyon, L., S. Tremblay, L. Bourgon, E. Wardrop, and M. G. Cordingley Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antivir. Res. 68: Reference deleted. 7. Hicks, C., for the RESIST-1 study team RESIST-1: randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir; phase 3 comparison of TPV/r and standard-of-care boosted-comparator PI (CPI/r) at 24 weeks. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C.. 8. Johnson, V. A., F. Brun-Vezinet,, B. Clotet, B. Conway, R. T. D Aquila, L. M. Demeter, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, A. Telenti, and D. D. Richman Drug resistance mutations in HIV-1. Topics HIV Med. 11: Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, D. Pillay, J. Schapiro, A. Telenti, and D. Richman Update of the drug resistance mutations in HIV-1: Topics HIV Med. 13: Kohlbrenner, V., J. Gathe, G. Pierone, K. Arasteh, P. Rubio, R. LaLonde, P. Piliero, S. McCallister, S. Garfinkel, R. Chaves, S. Spinosa, C. Dohnanyi, A. Quinson, and D. Mayers Tipranavir/ritonavir (TPV/r) demonstrates potent efficacy in multiple protease-inhibitor (PI)-experienced patients at 24 weeks: BI Presented at the 9th European AIDS Conference, Warsaw, Poland, 26 to 29 October. 11. Larder, B. A., K. Hertogs, S. Bloor, C. van den Eyne, W. DeCian, W. Yenyun, W. W. Freimuth, and G. Tarpley Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14: Mayers, D., K. Curry, V. Kohlbrenner, and S. McCallister Nonpeptidic protease inhibitors (NPPIs): tipranavir. Adv. Antiviral Drug Res. 4: Menendez-Arias, L Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23: Muzammil, S., L. W. Kang, A. A. Armstrong, A. Jakalian, P. R. Bonneau, V. Schmelmer, L. M. Amzel, and E. Freire Binding energetics analysis shows a unique response of tipranavir to HIV-1 protease mutations associated with drug resistance. Presented at the 3rd International AIDS Society meeting, Rio de Janeiro, Brazil, 24 to 27 July. 15. Muzammil, S., L. W. Kang, A. A. Armstrong, A. Jakalian, P. R. Bonneau, V. Schmelmer, L. M. Amzel, and E. Freire Unique response of tipranavir to multi-drug resistant HIV-1 proteases suggests new ways of combating drug resistance. Presented at the 14th International HIV Drug Resistance Workshop, Quebec City, Canada, 7 to 11 June. 16. Perryman, A. L., J. H. Lin, and J. A. McCammon HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target for drugs. Protein Sci. 13: Poppe, S. M., D. E. Slade, K. T. Chong, R. R. Hinshaw, P. J. Pagano, M. Markowitz, D. D. Ho, H. Mo, R. R. Gorman, T. J. Dueweke, S. Thaisrivongs, and W. G. Tarpley Antiviral activity of the dihydropyrone PNU , a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41: Puchhammer-Stoeckl, E., C. Steininger, E. Geringer, and F. X. Heinz Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains. HIV Med. 3: Rusconi, S., S. la Seta Catamancio, P. Citterio, S. Kurtagic, M. Violin, C. Balotta, M. Moroni, M. Galli, and A. D Arminio-Monforte Susceptibility to PNU (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. 44: Shafer, R. W., O. Hsu, A. K. Patick, C. Craig, and V. Brendel Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J. Virol. 73: Shafer, R. W., D. Stevenson, and B. Chan Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 27: Thaisrivongs, S., H. I. Skulnick, S. R. Turner, J. W. Strohbach, R. A. Tommasi, P. D. Johnson, P. A. Aristoff, T. M. Judge, R. B. Gammill, J. K. Morris, K. R. Romines, R. A. Chrusciel, R. R. Hinshaw, K. T. Chong, W. G. Tarpley, S. M. Poppe, D. E. Slade, J. C. Lynn, M. M. Horng, P. K. Tomich, E. P. Seest, L. A. Dolak, W. J. Howe, G. M. Howard, F. J. Schwende, L. N. Toth, G. E. Padbury, G. J. Wilson, L. Shiou, G. L. Zipp, K. F. Wilkinson, B. D. Rush, M. J. Ruwart, K. A. Koeplinger, Z. Zhao, S. Cole, R. M. Zaya, T. J. Kakuk, M. N. Janakiraman, and K. D. Watenpaugh Structurebased design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J. Med. Chem. 39: Valdez, H., D. B. Hall, V. M. Kohlbrenner, C. A. Boucher, J. Schapiro, J. Baxter, J. Scherer, S. McCallister, and D. L. Mayers Non-response to tipranavir is associated with pretreatment resistance characterized by tipranavir phenotype or genotypic tipranavir score. Antivir. Ther. 10:S29.
Tipranavir (TPV) Genotypic Inhibitory Quotient Predicts Virological Response at 48 Weeks to TPV-Based Salvage Regimens
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 28, p. 166 171 Vol. 52, No. 3 66-484/8/$8. doi:1.1128/aac.163-7 Copyright 28, American Society for Microbiology. All Rights Reserved. Tipranavir (TPV) Genotypic
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationTipranavir (TPV) genotypic Inhibitory Quotient (giq) predicts Virological Response at 48 weeks to TPV-based salvage regimens.
AAC Accepts, published online ahead of print on December 00 Antimicrob. Agents Chemother. doi:.1/aac.0-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More informationDepartment of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy 7
Antiviral Therapy 2010 15:1011 1019 (doi: 10.3851/IMP1670) Original article Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation
More information7Original articlehaart and correlated pathologies ~ N 1
Paola Di Vincenzo*, Giampiero Carosi, Gioacchino Angarano, Giovanni Di Perri, Paolo Grossid, Francesco Mazzotta#, Giuseppe Pastore**, Fredy Suter, Fulvio Adorni, Stefano Bonora, Valeria Micheli, Antonietta
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationTitle. HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in
Title HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance October 13, 2004 Authors SY Rhee
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationScottish Medicines Consortium
Scottish Medicines Consortium darunavir 300mg tablets (Prezista ) No. (378/07) Tibotec (a division of Janssen-Cilag Ltd) 4 May 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationThe US Food and Drug Administration has
NEW ANTIRETROVIRAL AGENTS FOR TREATMENT-EXPERIENCED PATIENTS * Roy M. Gulick, MD, MPH ABSTRACT Antiretroviral treatment regimens currently available for the treatment of the human immunodeficiency virus
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationORIGINAL ARTICLE /j x. Brescia, Italy
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00938.x Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive
More informationThe Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4
Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish
More informationManagement of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationThe advent of protease inhibitors (PIs) as PROCEEDINGS CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD
CLINICAL EXPECTATIONS OF EFFICACY: PROTEASE INHIBITOR POTENCY * Benjamin Young, MD, PhD ABSTRACT Tremendous strides were made in reducing the morbidity and mortality associated with HIV infection with
More informationBecause accurate and reproducible phenotypic susceptibility
BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationMilan, Italy. Received 15 March 2002; returned 22 July 2002; revised 12 September 2002; accepted 27 September 2002
Journal of Antimicrobial Chemotherapy (2003) 51, 135 139 DOI: 10.1093/jac/dkg016 Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay
More informationHIV/AIDS CID 2003:37 (1 July) 113
MAJOR ARTICLE HIV/AIDS Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society USA Panel Martin S. Hirsch,
More informationThe Genetic Barrier to Resistance
The Genetic Barrier to Resistance Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Beijing, May 2013 The Genetic Barrier to Resistance The genetic
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationReceived 13 December 2001/Accepted 11 March 2002
JOURNAL OF VIROLOGY, July 2002, p. 6836 6840 Vol. 76, No. 13 0022-538X/02/$04.00 0 DOI: 10.1128/JVI.76.13.6836 6840.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. A Mutation
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationSpecial Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel
Special Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel In 1996 the International AIDS Society USA convened an international panel of experts
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationFrançois Raffi, 1 Christine Katlama, 2 Michael Saag, 3 Martin Wilkinson, 6 Jain Chung, 5 Lynn Smiley, 4 and Miklos Salgo 5
HIV/AIDS MAJOR ARTICLE Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO)
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationDrug Resistance Mutations in HIV-Infected Patients Failing Tipranavir and Darunavir in the Spanish Drug Resistance Database
AAC Accepts, published online ahead of print on 17 May 2010 Antimicrob. Agents Chemother. doi:10.1128/aac.00160-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 PREZISTA 400 mg, film-coated tablet B/60 (CIP code: 393 138-3) Applicant: JANSSEN-CILAG darunavir
More informationInteraction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2005, p. 4903 4910 Vol. 49, No. 12 0066-4804/05/$08.00 0 doi:10.1128/aac.49.12.4903 4910.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More information10 : 4. Introduction. R Sajithkumar, Kottayam. Mutations to select agents: Evolution:
10 : 4 HIV drug resistance and second line of ART Introduction The first response to the HIV epidemic identified as AIDS in 1981- was the feeling of helplessness. The cause of the illness was soon identified
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationGlobal Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2003, p. 350 359 Vol. 47, No. 1 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.1.350 359.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationVirological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication
Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationDIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA:
Atazanavir (BMS-232632, ATV) Molecular Formula: C 38 H 52 N 6 O 7 H 2 SO 4 Molecular Weight: 704.9 Dosage Form(s): 100/150/200 mg capsule Route(s) of Administration: Oral Pharmacological Category: Indication(s):
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationClinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy
8 The Open Virology Journal, 2007, 1, 8-13 Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy Harout K. Tossonian 1, Jesse D. Raffa 2, Jason Grebely
More information1592U89 (Abacavir) Resistance and Phenotypic Resistance Testing
1592U89 (Abacavir) Resistance and Phenotypic Resistance Testing Reported by Jules Levin, Executive Director of NATAP (3 March 1998) The following report contains a comprehensive update of the latest information
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationTreatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
Send Orders for Reprints to reprints@benthamscience.ae 38 The Open AIDS Journal, 2015, 9, 38-44 Open Access Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing
More informationAntiviral Therapy 2011; 16: (doi: /IMP1851)
Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure
More informationARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za
ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action
More informationHarvard School of Public Health, Boston, Massachusetts; 2. University Hospital, Utrecht University, Utrecht, The Netherlands; 3
59 Methods for Investigation of the Relationship between Drug-Susceptibility Phenotype and Human Immunodeficiency Virus Type 1 Genotype with Applications to AIDS Clinical Trials Group 333 Anne D. Sevin,
More informationAntiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh
Antiretroviral Prophylaxis and HIV Drug Resistance John Mellors University of Pittsburgh MTN Annual 2008 Outline Two minutes on terminology Origins of HIV drug resistance Lessons learned from ART Do these
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationReceived 8 May 2008/Returned for modification 16 June 2008/Accepted 7 August 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2008, p. 4050 4056 Vol. 52, No. 11 0066-4804/08/$08.00 0 doi:10.1128/aac.00605-08 Copyright 2008, American Society for Microbiology. All Rights Reserved. Virologic
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationAntiviral Therapy 2011; 16: (doi: /IMP1719)
Antiviral Therapy 2011; 16:99 108 (doi: 10.3851/IMP1719) Original article Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationPrinciples of HIV Drug Resistance: Resistance to New Drug Classes. Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada
Principles of HIV Drug Resistance: Resistance to New Drug Classes Mark A Wainberg McGill University AIDS Centre Montreal, Quebec, Canada Why Is It Important to Understand HIV Drug Resistance? 1. Resistance
More informationBonaventura Clotet. HIV Unit & Retroviroloy Lab Univ Hosp Germans Trias i Pujol Badalona, Catalonia, Spain
Cost-cutting measures to reduce the antiretroviral prescription bill under an urgent government requirement due to the economic crisis. A Spanish view. Bonaventura Clotet. HIV Unit & Retroviroloy Lab Univ
More informationModels of HIV during antiretroviral treatment
Models of HIV during antiretroviral treatment Christina M.R. Kitchen 1, Satish Pillai 2, Daniel Kuritzkes 3, Jin Ling 3, Rebecca Hoh 2, Marc Suchard 1, Steven Deeks 2 1 UCLA, 2 UCSF, 3 Brigham & Womes
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationHIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital
HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per
More informationAWMSG Secretariat Assessment Report Advice no Darunavir (Prezista
AWMSG Secretariat Assessment Report Advice no. 0311 Darunavir (Prezista ) for the treatment of HIV-1 infection in treatment-experienced children and adolescents This assessment report is based on evidence
More informationGenotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen
Original Article Genotypic Resistance in HIV-infected Patients Failing a d4t/3tc/nvp Regimen Somnuek Sungkanuparph, M.D.* Weerawat Manosuthi, M.D.* Sasisopin Kiertiburanakul, M.D.* Wasun chantratita, Ph.D.**
More informationAntiviral Therapy 7:
Antiviral Therapy 7:165 174 Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir
More informationImmune pressure analysis of protease and reverse transcriptase genes of primary HIV-1 subtype C isolates from South Africa
African Journal of Biotechnology Vol. 10(24), pp. 4784-4793, 6 June, 2011 Available online at http://www.academicjournals.org/ajb DOI: 10.5897/AJB10.560 ISSN 1684 5315 2011 Academic Journals Full Length
More informationThe E138A substitution in HIV-1 reverse transcriptase decreases in vitro. susceptibility to emtricitabine as indicated by competitive fitness assays
AAC Accepts, published online ahead of print on 13 January 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02114-13 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 The E138A
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More information43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) A Cutrell, J Hernandez, M Edwards, J Fleming, W Powell, T Scott
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster H-2013 Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Retrospective Analysis of Over 8,000 Subjects
More informationIt takes more than just a single target
It takes more than just a single target As the challenges you face evolve... HIV mutates No HIV-1 mutation can be considered to be neutral 1 Growing evidence indicates all HIV subtypes may be prone to
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationTRANSPARENCY COMMITTEE OPINION. 10 March 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 APTIVUS 250 mg, soft capsule Bottle of 120 capsules (CIP: 369 252-4) Applicant: BOEHRINGER INGELHEIM
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationPediatric Patient Information:
New pediatric dosing information for Aptivus, patients 2-18 years of age, approval of New Oral Solution and information on coadministration with midazolam Aptivus (tipranavir) is now available as an oral
More informationPersisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up
Antiviral Therapy 5: 65-70 Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up P Clevenbergh 1 *, J Durant 1, P Halfon
More informationAntiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
More informationThe prevalence of antiretroviral drug resistance in the United States
The prevalence of antiretroviral drug resistance in the United States Douglas D. Richman a,b, Sally C. Morton c, Terri Wrin d, Nicholas Hellmann d, Sandra Berry c, Martin F. Shapiro c,e and Samuel A. Bozzette
More informationUpdate on HIV-1 Drug Resistance and Tropism Testing
Update on HIV-1 Drug Resistance and Tropism Testing Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and Women s Hospital Harvard Medical School ACTHIV 2011: A State-of-the-Science Conference
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationRecognition of HIV-1 subtypes and antiretroviral drug resistance using weightless neural networks
Recognition of HIV-1 subtypes and antiretroviral drug resistance using weightless neural networks Caio R. Souza 1, Flavio F. Nobre 1, Priscila V.M. Lima 2, Robson M. Silva 2, Rodrigo M. Brindeiro 3, Felipe
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationPrinciples of HIV resistance testing and overview of assay performance characteristics
Principles of HIV resistance testing and overview of assay performance characteristics Douglas D Richman Antiviral Therapy 5: 27-31 Departments of Pathology and Medicine, San Diego VA Medical Center and
More informationGenotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance
CLINICAL MICROBIOLOGY REVIEWS, Apr. 2002, p. 247 277 Vol. 15, No. 2 0893-8512/02/$04.00 0 DOI: 10.1128/CMR.15.2.247 277.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved. Genotypic
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationOriginal article Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy
Antiviral Therapy 14:359 369 Original article Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy Simona Di Giambenedetto 1 *, Maurizio
More informationA new approach for 'deep salvage' trials in advanced HIV infection [OPINION]
A new approach for 'deep salvage' trials in advanced HIV infection [OPINION] AIDS:Volume 21(12)31 July 2007p 1503-1506 Lederman, Michael Ma; Miller, Veronicab; Weller, Ianc; Deeks, Steven Gd >From the
More informationInteractive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1
Antiviral Therapy 10:551 555 Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1 Mina John, Corey B Moore, Ian R James and Simon A Mallal* Centre for Clinical
More informationPersistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome
J Antimicrob Chemother 2012; 67: 2231 2235 doi:10.1093/jac/dks191 Advance Access publication 29 May 2012 Persistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationTransmission of integrase resistance HIV
Transmission of integrase resistance HIV Charles Boucher, MD, PhD Clinical Virology, Dept. Viroscience, Erasmus Medical Center, Erasmus Universiy, The Netherlands Major resistance mutations (Stanford)
More informationINTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING
INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING Dr. Danni Kirwan ID/Microbiology SpR St. George s Hospital, London ARV initiation in treatment-naïve patients BHIVA,
More informationICAAC/IDSA DC, Oct. 26, 2008
Tenofovir (TDF)- or Abacavir (ABC)-selected Minority Subpopulations in Viremic Subjects Detected by Ultra-deep Sequencing R. T. D Aquila 1, E. Rouse 2, J. Horton 2, A. Kheshti 1,3, S. Raffanti 1,3, K.
More informationThe impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors
Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 106(2): 177-181, March 2011 177 The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More information